BMI OrganBank

Cover Block

Field	Value
Name	BMI OrganBank
Tagline	Develops medical devices and perfusion technology to improve organ and tissue preservation for transplantation
Headquarters	Winston-Salem, NC, USA (additional facility at Research Triangle Park, NC)
Stage	Seed
Business Model	B2B (medical devices, clinical research services)
Industry	Healthtech / Medical Devices
Technology Type	Biotech / Life Sciences (ex vivo organ perfusion)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2): Carrie DiMarzio, George Barr
Funding Label	Seed
Total Disclosed	$600,000 seed plus $3,500,000 grant funding [Crunchbase] [BMI OrganBank]

Links

• Website: https://bmiorganbank.com/
• LinkedIn: https://www.linkedin.com/company/bmiorganbank
• Crunchbase: https://www.crunchbase.com/organization/bmi-organbank

What an Investor Needs First

BMI OrganBank is a Winston-Salem, North Carolina medical device company building ex vivo perfusion and preservation technology aimed at extending the viable transport window for transplantable organs, with an initial focus on kidneys [BMI OrganBank] [Crunchbase]. The company traces its commercial roots to BioMedInnovations, LLC, founded by industry veteran George Barr, and is now led by co-founder and CEO Carrie DiMarzio, who previously guided BMI's SuppleVent ventilator through FDA Emergency Use Authorization during the COVID-19 pandemic [BMI OrganBank]. Its flagship portable kidney preservation device, co-developed with surgeons at Duke University's Ex-Vivo Organ Lab (DEVOL), has secured FDA Breakthrough Device Designation [BMI OrganBank]. Disclosed capitalization to date includes a $600,000 seed round and roughly $3,500,000 in grant funding [Crunchbase] [BMI OrganBank]. The business model combines device commercialization with a fee-for-service preclinical research arm, the Ex Vivo Institute [BMI OrganBank]. Over the next 12 to 18 months, the items most worth watching are the start of clinical studies for the portable kidney device, FDA clearance progress for the broader OrganBank system, and the operational impact of a recently announced partnership with Dedicated Staffing Solutions [BMI OrganBank] [PR Newswire].

Data Accuracy: GREEN -- Confirmed by BMI OrganBank primary materials, Crunchbase, and PR Newswire.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech / Transplantation Medical Devices
Technology Type	Biotech / Life Sciences (ex vivo perfusion)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed plus federal grant funding

Inside the Company

BMI OrganBank is the current operating identity of BioMedInnovations, LLC, a North Carolina medical device developer founded by George Barr [BMI OrganBank]. The company operates from facilities at the Wake Forest Institute for Regenerative Medicine (WFIRM) campus in Winston-Salem and at Research Triangle Park [BMI OrganBank].

During the COVID-19 pandemic, BMI developed the SuppleVent ventilator and secured FDA Emergency Use Authorization, an effort led by Carrie DiMarzio [BMI OrganBank]. The transplantation chapter began with a perfusion technology license from Duke University's Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig [BMI OrganBank]. That license underpins the OrganBank Transport device and the portable kidney preservation device.

Key milestones include the founding of BioMedInnovations by Barr, the SuppleVent EUA, the Duke perfusion technology license, the launch of the Ex Vivo Institute services arm, the award of FDA Breakthrough Device Designation for the kidney preservation device, and the 2024-era strategic partnership with Dedicated Staffing Solutions [BMI OrganBank] [PR Newswire].

Data Accuracy: GREEN -- Confirmed by BMI OrganBank primary site, PR Newswire, and Crunchbase.

Under the Hood

BMI OrganBank's product portfolio is organized around a proprietary ex vivo organ perfusion platform marketed under the OrganBank brand [BMI OrganBank]. The flagship clinical product is a portable kidney preservation device, co-developed with leading transplant surgeons [BMI OrganBank]. The kidney device received FDA Breakthrough Device Designation [BMI OrganBank]. A second device line, the OrganBank Transport, was co-developed with Duke University's DEVOL lab [BMI OrganBank].

Beyond devices, BMI runs two adjacent platforms. The Ex Vivo Institute offers customized preclinical translational research services for ex vivo and in vivo studies [BMI OrganBank]. The OrganBank Lab markets a patented cardio-vascular emulating system branded CaVESWave for ex vivo pharmacodynamic research [BMI OrganBank].

The underlying intellectual property combines licensed perfusion technology from the Duke Ex-Vivo Organ Lab with BMI's own patents, methods, and trade secrets in organ perfusion and preservation [BMI OrganBank].

Data Accuracy: GREEN -- Confirmed by BMI OrganBank product pages.

Market Research and Opportunity

BMI OrganBank is targeting kidney transplantation first, the highest-volume solid-organ transplant category in the United States, and is building a platform with claimed applicability across additional organs and into preclinical research services [BMI OrganBank]. The Ex Vivo Institute services line and the CaVESWave research platform extend the addressable demand into pharmaceutical R&D budgets [BMI OrganBank].

The company's recent partnership with Dedicated Staffing Solutions addresses operational constraints on the transplant center side [PR Newswire]. Adjacent and substitute markets include hypothermic and normothermic machine perfusion systems and conventional cold static storage [BMI OrganBank].

Sizing claim	Value
Disclosed seed funding	$600,000
Disclosed grant funding	$3,500,000
Kidney device regulatory status	FDA Breakthrough Device Designation

Data Accuracy: YELLOW -- Regulatory and funding facts confirmed; market sizing not independently cited.

Competition and Substitutes

BMI OrganBank competes in ex vivo organ perfusion and preservation. Incumbent machine perfusion device makers hold the installed base inside major U.S. transplant centers [BMI OrganBank]. Challenger device makers compete on portability, cost per use, and clinical workflow integration [BMI OrganBank]. Adjacent substitutes include the entrenched cold static storage workflow [BMI OrganBank].

BMI's defensibility includes the Duke Ex-Vivo Organ Lab license and named clinical collaborators (Drs. Barbas and Hartwig) [BMI OrganBank]. FDA Breakthrough Device Designation grants more frequent FDA interaction [BMI OrganBank]. The Winston-Salem and Research Triangle Park footprint provides proximity to the Wake Forest Institute for Regenerative Medicine [BMI OrganBank].

Data Accuracy: YELLOW -- Subject facts confirmed; competitor identities not named in captured sources.

Opportunity

BMI's most plausible upside is becoming the default portable kidney preservation device used by mid-market and academic U.S. transplant centers, with a secondary platform business in fee-for-service ex vivo research [BMI OrganBank].

Growth scenarios.

Scenario	What happens	Catalyst
Kidney-first beachhead	Portable kidney device completes initial clinical study, secures FDA clearance, and lands inside a first cohort of academic transplant centers	Initiation and readout of the clinical study [BMI OrganBank]
Multi-organ platform	OrganBank Transport device launches and the platform extends from kidney to additional organs	Commercial launch of OrganBank Transport [BMI OrganBank]
Services and tools flywheel	Ex Vivo Institute and CaVESWave generate non-dilutive revenue from pharma and academic clients	Continued contract research revenue and grant funding [BMI OrganBank]

Data Accuracy: YELLOW -- Regulatory, license, and funding evidence confirmed; scenario sizing is structural.

Sources

1. [BMI OrganBank] BMI OrganBank: Transforming Transplantation | https://bmiorganbank.com/
2. [BMI OrganBank] A New VISION: Groundbreaking Collaboration Advances Whole Eye Transplants | https://bmiorganbank.com/whole-eye-transplants/
3. [BMI OrganBank] Our Company | https://bmiorganbank.com/our-company/
4. [BMI OrganBank] BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology | https://bmiorganbank.com/bmi-organbank-secures-fda-breakthrough-device-designation-for-innovative-kidney-transplant-technology/
5. [BMI OrganBank] Bios | https://bmiorganbank.com/bios/
6. [BMI OrganBank] Investors & News | https://bmiorganbank.com/investors-and-news/
7. [BMI OrganBank] Ex Vivo Institute Perfusion Research Expert Services | https://bmiorganbank.com/perfusion-research-expert-services/
8. [BMI OrganBank] OrganBank Lab Pharmacodynamic Research Platform | https://bmiorganbank.com/organbank-lab-pharmacodynamic-research-platform/
9. [BMI OrganBank] BMI OrganBank Selected by the North Carolina Biotechnology Center for Funding | https://bmiorganbank.com/ncbiotech/
10. [Crunchbase] BMI OrganBank Company Profile & Funding | https://www.crunchbase.com/organization/bmi-organbank
11. [LinkedIn] BMI OrganBank Company Page | https://www.linkedin.com/company/bmiorganbank
12. [LinkedIn] Carrie DiMarzio CEO/Co-Founder/Board Director | https://www.linkedin.com/in/carrie-dimarzio-26319257/
13. [LinkedIn] George Barr | https://www.linkedin.com/in/george-barr-5698685/
14. [LinkedIn] Tyler Adcock BMI OrganBank | https://www.linkedin.com/in/tyler-adcock-5980081a7/
15. [LinkedIn] Josh Copus, PhD BMI OrganBank | https://www.linkedin.com/in/josh-copus-phd-316975a1/
16. [Innovation Quarter] Meet the Organ Preservation Technology That Will Save Lives | https://www.innovationquarter.com/articles/how-bmi-organbank-is-changing-the-kidney-transplant-equation/
17. [North Carolina Biotechnology Center] FDA grants Breakthrough Device status to BMI OrganBank's kidney preservation device | https://www.ncbiotech.org/news/fda-grants-breakthrough-device-status-bmi-organbanks-kidney-preservation-device
18. [PR Newswire] BMI OrganBank Announces Strategic Partnership with Dedicated Staffing Solutions | https://www.prnewswire.com/news-releases/bmi-organbank-announces-strategic-partnership-with-dedicated-staffing-solutions-to-align-advanced-preservation-technology-with-clinical-staffing-expertise-302694059.html